Inclusion Criteria:  Subject provides written informed consent prior to initiation of any study procedures. Understands and agrees to comply with planned study procedures. Adult ≥18 years of age at time of enrollment, pediatric ages will be excluded.  Subject consents to receiving a COVID-19 positive organ (kidney, liver, or heart)  a. Deceased immunocompetent donor with positive SARS-CoV-2 RT-PCR testing from the respiratory tract (upper or lower): i. Within 21 days since the date of COVID-19 diagnosis OR ii. Within 90 days since the date of COVID-19 diagnosis  Subject is confirmed COVID-19 negative confirmed by PCR at time of transplant with no signs and symptoms consistent with COVID-19 All candidates must be fully vaccinated 2 weeks prior to enrollment a. When applicable candidates can receive a booster vaccine as defined by the FDA/CDC  Exclusion Criteria:  Any exposure to investigational medications targeting COVID-19 Previous use of casirivimab with imdevimab antibody cocktail (REGEN-COV) Previous treatment of COVID-19 with a monoclonal antibody Active COVID-19 infection Allergy to casirivimab with imdevimab Pregnant patients Prior transplant Hepatitis C virus/NCT positive deceased donors